Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Reduced intraoperative pupil diameter and its underlying causes in patients undergoing phacoemulsification cataract surgery at a single center

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cataract Complications Management

Venue: Poster Village: Pod 1

First Author: : M.Belovari CROATIA

Co Author(s): :    H. Baric   A. Husic           

Abstract Details

Purpose:

To assess the incidence of intraoperative miosis (IM) in patients undergoing cataract surgery and identify its association with concurrent medications, ocular and systemic conditions.

Setting:

Department of Ophthalmology, County Hospital ńĆakovec, Croatia

Methods:

Patients undergoing cataract surgery at our department between February 2016 and February 2017 were prospectively enrolled. Data were collected on patient age and sex, the occurrence of IM and concurrent medications (alpha-blockers for prostate hyperplasia), ocular (glaucoma), and systemic diseases (any disease known to be related to IM).

Results:

IM was observed in 30 of 270 cases (11.1 %). Sixteen of those 30 patients (53.3 %) were men with a history of using alpha-blockers. Three patients (10%) had a history of glaucoma, and eleven (36.6 %) patients with IM had a systemic condition. Of the 30 IM cases, 18 (60%) were successfully resolved with intracameral use of medications, cohesive OVD, pupil stretching technique and vertical chop technique in posterior chamber; in eleven (36.6%) phacoemulsification was performed in the anterior chamber (phaco-out technique); and iris retractors were used in one case (3.3%).

Conclusions:

IM is a relatively frequent complication in cataract surgery, largely related to sistemic/ocular conditions or use of alpha-blockers. Intracameral use of medications, pupil stretching technique, vertical chop technique, phaco-out technique, and iris retractors are all effective in resolving IM.

Financial Disclosure:

NONE

Back to previous